^
    1m
    SCHEMBL4796824: a multifaceted antitumor agent targeting microtubule dynamics, DNA damage, and Wnt/β-catenin signaling in ovarian cancer cells. (PubMed, J Ovarian Res)
    SCHEMBL4796824, a BPR0L075 derivative with antitumor properties, targets tubulin's colchicine binding site and induces DNA damage response in ovarian cancer...Notably, these effects were more pronounced in c-MYC amplified SK-OV-3 cells. In summary, SCHEMBL4796824 disrupts the canonical Wnt/β-catenin signaling, inducing DNA damage, and inhibits the Wnt/β-catenin/c-MYC axis, triggering cellular senescence in a pathway-dependent manner, hinting at a novel therapeutic approach.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CHEK2 (Checkpoint kinase 2)
    |
    SB01
    over2years
    To Evaluate the Efficacy and Safety of SCB01A in Subjects With r/m Squamous Cell Head and Neck Cancer (clinicaltrials.gov)
    P2, N=10, Terminated, SynCore Biotechnology Co., Ltd. | N=37 --> 10
    Enrollment change • Metastases
    |
    SB01
    over2years
    To Evaluate the Efficacy and Safety of SCB01A in Subjects With r/m Squamous Cell Head and Neck Cancer (clinicaltrials.gov)
    P2, N=37, Terminated, SynCore Biotechnology Co., Ltd. | N=10 --> 37
    Enrollment change • Metastases
    |
    SB01